Skip to main content
. Author manuscript; available in PMC: 2013 Jul 17.
Published in final edited form as: Int J Interferon Cytokine Mediat Res. 2010 Jan 1;2010(2):9–21. doi: 10.2147/IJICMR.S6690

Figure 2.

Figure 2

Effect of cotransfecting dominant negative NF-κB pathway effectors on LPS induction of IL-6 or NF-κB-based promoters. A, Diagram of the known NF-κB pathways indicating the point of inhibition by the dominant negative effectors. B, C2C12 myocytes were cotransfected with the indicated dominant negative expression vector(s) and a luciferase reporter under the control of the wild-type (WT) IL-6 promoter (IL6-651Luc) in the presence or absence of LPS as described in “Experimental Procedures.” C, C2C12 myocytes were cotransfected with the indicated dominant negative expression vectors and a luciferase reporter under the control of a wild-type NF-κB-based promoter (NF-κBLuc) in the presence or absence of LPS as described in “Experimental Procedures.”

Notes: The results shown represent the mean ± SEM of 4 independent experiments. Promoter activity is presented as fold increase over the wild-type control transfection under basal conditions. Data from each treatment group were analyzed separately by unpaired Student’s t-test to determine treatment effect. *P < 0.5, compared to control value from the same treatment group.